← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 2, 2020Last known activity
Aug 1, 2025
Timeline
No events for the selected filters.
Drugs by trial phase (13 distinct, 14 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
Recent trials (20)
- NCT07074106Lead sponsorPhase 2Aug 1, 2025
- NCT06002841Lead sponsorPhase 1/Phase 2Feb 1, 2024
- NCT05900973Lead sponsorPhase 2Jul 20, 2023
- NCT05812586Lead sponsorPhase 3Mar 14, 2023
- NCT05470803Lead sponsorPhase 3Aug 31, 2022
- NCT05146843Lead sponsorN/ADec 2, 2021
- NCT05146843Reponsible party - principal investigatorN/ADec 2, 2021
- NCT05087368Lead sponsorPhase 2Dec 1, 2021
- NCT04800224Reponsible party - principal investigatorPhase 2/Phase 3Apr 12, 2021
- NCT04800224Lead sponsorPhase 2/Phase 3Apr 12, 2021
- NCT04756830Lead sponsorPhase 4Feb 19, 2021
- NCT04756830Reponsible party - principal investigatorPhase 4Feb 19, 2021
- NCT04573855Lead sponsorPhase 1/Phase 2Dec 1, 2020
- NCT04528368Lead sponsorPhase 2Aug 18, 2020
- NCT04528368Overall official - principal investigatorPhase 2Aug 18, 2020
Details
- Last known activity
- Aug 1, 2025